Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
Percodan is an oral tablet combining aspirin and oxycodone hydrochloride, a potent opioid analgesic used for moderate to severe pain management. The oxycodone component acts as a mu-opioid receptor agonist while aspirin provides additional anti-inflammatory and analgesic effects. This combination product has been a cornerstone of pain management since its approval in 1950.
With approaching loss of exclusivity and moderate competitive pressure (30%), brand teams are likely consolidating resources and shifting focus to retention and managed care strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Percodan offers limited growth trajectory but valuable expertise in legacy product management, complex opioid regulations (DEA Schedule II), and managed care navigation during market contraction. This role suits professionals seeking stability and deep regulatory/compliance knowledge rather than rapid career advancement in a growth product.
Worked on PERCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.